Cite this: *Org. Biomol. Chem.*, 2018, **16**, 1843

Identification of a novel ligand for the ATAD2 bromodomain with selectivity over BRD4 through a fragment growing approach†

Duncan C. Miller,^{‡a} Mathew P. Martin,^{‡a} Santosh Adhikari,^{‡a} Alfie Brennan,^{‡a} Jane A. Endicott,^b Bernard T. Golding,^{‡a} Ian R. Hardcastle,^a Amy Heptinstall,^a Stephen Hobson,^a Claire Jennings,^b Lauren Molyneux,^a Yvonne Ng,^b Stephen R. Wedge,^b Martin E. M. Noble^{*b} and Celine Cano^{*a}

ATAD2 is an ATPase that is overexpressed in a variety of cancers and associated with a poor patient prognosis. This protein has been suggested to function as a cofactor for a range of transcription factors, including the proto-oncogene MYC and the androgen receptor. ATAD2 comprises an ATPase domain, implicated in chromatin remodelling, and a bromodomain which allows it to interact with acetylated histone tails. Dissection of the functional roles of these two domains would benefit from the availability of selective, cell-permeable pharmacological probes. An *in silico* evaluation of the 3D structures of various bromodomains suggested that developing small molecule ligands for the bromodomain of ATAD2 is likely to be challenging, although recent reports have shown that ATAD2 bromodomain ligands can be identified. We report a structure-guided fragment-based approach to identify lead compounds for ATAD2 bromodomain inhibitor development. Our findings indicate that the ATAD2 bromodomain can accommodate fragment hits ($M_r < 200$) that yield productive structure–activity relationships, and structure-guided design enabled the introduction of selectivity over BRD4.

Received 12th January 2018,
Accepted 15th February 2018

DOI: 10.1039/c8ob00099a

rsc.li/obc

Introduction

Histone proteins undergo several post translational modifications (PTMs) that affect DNA transcription, replication and repair, and genomic architecture.¹ Histone PTMs are regulated by three groups of proteins known as writers, erasers and readers. Bromodomains are a class of protein interaction modules, conserved across evolution, which recognise ϵ -N-acetyl lysine PTMs.² A total of 61 bromodomains in 46 diverse proteins have been identified in the human proteome, and these are divided into eight structural classes. Within subfamily IV in the structure-based classification of bromodomain-containing proteins is ATAD2 (ATPase Family, AAA Domain Containing 2). ATAD2 is overexpressed in a wide range of human cancers,

including breast, lung, and prostate carcinomas, and it is present in low levels in normal non-tumour cells.^{3–5} The overexpression of ATAD2 has been associated with a poor patient outcome to treatment in breast,⁶ lung,⁷ ovarian,⁸ hepatocellular,⁹ endometrial¹⁰ and gastric¹¹ cancers. Functionally, ATAD2 has been shown to act as a coactivator of various transcription factors including the androgen receptor (AR),⁴ and the proto-oncogene MYC,⁵ and studies examining gene silencing of ATAD2, using siRNA or shRNA, report it to have a role in tumour cell proliferation and survival.^{3,12} These studies suggest that ATAD2 is a potential target for cancer drug discovery, and small-molecule inhibitors would provide insight into the phenotypic response to the inhibition of ATAD2.

ATAD2 comprises a four helical bundle (α_Z , α_A , α_B , α_C) and two loops (ZA and BC). The acetyllysine binding pocket, created by helices α_B , α_C and the ZA loop, is polar and shallow compared to several other bromodomains.¹³ The ZA loop of ATAD2, which forms a major part of the binding site is polar, whereas, the binding site in the bromodomain BRD4 is mostly hydrophobic.¹⁴ The flexibility of the ZA loop coupled to the shallow and polar nature of the binding site resulted in the druggability of the ATAD2 bromodomain being classified as ‘difficult’.^{13,14}

Compounds **1** and **2a–b** were recently disclosed as relatively potent inhibitors of the bromodomain of ATAD2.^{15–17}

^aNewcastle Drug Discovery, Northern Institute for Cancer Research, School of Chemistry, Newcastle University, Newcastle upon Tyne, NE1 7RU, UK.

E-mail: celine.cano@ncl.ac.uk; Tel: +44 (0)191 208 7060

^bNewcastle Drug Discovery, Northern Institute for Cancer Research, Paul O’Gorman Building, Medical School, Framlington Place, Newcastle upon Tyne NE2 4HH, UK.

E-mail: martin.noble@ncl.ac.uk; Tel: +44 (0)191 208 4466

†Electronic supplementary information (ESI) available. See DOI: 10.1039/c8ob00099a

‡These authors contributed equally to the work described in this paper.

Scheme 1 Reagents and conditions: (a) Boc₂O, THF, Na₂CO₃, THF, r.t., 42 h, 95%; (b) (i) *s*-BuLi, THF, -78 °C, 15 min; (ii) CO₂ (dry ice), -78 °C to r.t., 45 min, 74%; (c) Ac₂O, tetrabutylammonium acetate, 65 °C, 1 h, 81%; (d) R¹ = Me: MeI, Cs₂CO₃, MeCN, 60 °C, 3 h, 78%; R¹ = Et: EtI, Cs₂CO₃, MeCN, 60 °C, 3 h, 51% (e) MeI, MeCN, 170 °C, μ W, 1 h, quant; (f) for compounds 14a–c (i) NaH, DMF, r.t., 15 min; (ii) ethyl iodide or benzyl bromide or (2-bromoethyl)benzene, r.t., 3 h, 61% (14a), 61%; (14b), 30% (14c); For compounds 14d–f: Cs₂CO₃, DMF, 100 °C, μ W, 30 min: 1-(2-chloroethyl)pyrrolidine hydrochloride 40% (14d), or 4-(2-chloroethyl)morpholine hydrochloride, 82% (14e), or (2-bromoethoxy)(*tert*-butyl)dimethylsilane, 55% (14f); (g) TBAF, THF, r.t., 18 h, 90%.

Compound **1** was not selective for ATAD2 over BRD4. Enhanced ATAD2 potency and selectivity over BRD4 was achieved in this series through introduction of a cyclic sulfone (**2a**) or a difluorocyclohexane moiety (**2b**). These groups form favourable interactions with the sidechains of Arg1007 and Arg1077 in the ATAD2 binding site, and achieve selectivity due to unfavourable interactions with lipophilic Trp81 and Met149 sidechains in BRD4. Compounds **3–5** were reported as ATAD2 inhibitors arising from a fragment screen,¹⁸ but the low potency of these fragments makes them unsuitable as chemical probes of ATAD2 function. More recently **BAY-850** (**6**) has been reported as a potent ATAD2 inhibitor arising from screening of a DNA-encoded library with an unusual dimer-inducing mode of action, although not BRD4 selectivity data was reported.¹⁹

This work describes the development of ATAD2 inhibitors employing structure-guided optimization of a fragment hit, with potential for development into selective chemical tools to investigate ATAD2 bromodomain function in biological systems.

Synthesis

Screening of a small targeted fragment library identified 1,6-dihydro-2*H*-pyrrolo[2,3-*c*]pyridine-2,5(3*H*)-dione **7** as a promising scaffold for the design of inhibitors of the ATAD2 bromodomain. Synthesis of the bicyclic template started with protection of commercially available 6-methoxy-4-methylpyridin-3-amine **8** as its *tert*-butyl carbamate to give **9** (Scheme 1). Deprotonation followed by quenching with carbon dioxide gave **10**. Acetic anhydride mediated ring closure in the presence of catalytic tetra-*N*-butylammonium acetate followed by

Scheme 2 Reagents and conditions: (a) RX, MeCN, 170 °C, μ W, 45 min, 22–93%; (b) MeI, Cs₂CO₃, DMF, 100 °C, μ W, 30 min, 74–94%; (c) NaOH, EtOH, H₂O, 100 °C, 23 h, 32%; Structures of 17a–q and 18a–b are given in Tables 2 and 3.

Scheme 3 Reagents and conditions: (a) RCHO, piperidine, THF, 100 °C, 30 min, 50–88%; (b) H₂, 10% Pd/C, THF, MeOH, r.t., 2 h; (c) MeI, Cs₂CO₃, DMF, 50 °C, 1.5 h, 55–56% over 2 steps; (d) 4-chlorobenzyl bromide, MeCN, 170 °C μ W, 45 min, 50–64%. Structures of 22a–f are given in Table 4.

bis-alkylation with iodomethane or iodoethane gave **12** and **13**, respectively. Deprotection and *N*-alkylpyridone formation was achieved in a single step by heating **12** with iodomethane to give compound **7**. Targets varying the *N*¹ substituent (**14a–f**) were synthesised by alkylation of **7**. **14f** was deprotected using TBAF to provide **14g**.

*N*⁶-Alkylated target compounds were synthesised from **12** or **13** under microwave irradiation using an array of alkyl halides

to give **15a–p** and **16a–b**, respectively. Subsequent *N*¹-methylation gave compounds **17a–q** and **18a–b** (Scheme 2).

Diversification of the *C*³-position could be achieved using Knoevenagel condensation of aldehydes with **11** to provide **19a–j** in high yield (Scheme 3). Subsequent alkene reduction, followed by methylation provided **21a–f**. Treatment of methoxy pyridines **21a–f** with benzyl bromides at high temperature provided the target pyridones (**22a–f**) in moderate yields.

Fig. 1 Binding of initial fragment hit **7**. (A) Binding mode of fragment hit **7** (yellow ball and stick) bound to ATAD2 (white). ATAD2 active site residues shown in cylinder and conserved water molecules shown as red spheres. Potential hydrogen bonding interactions shown in black dash. (B) 2D Interaction map of **7** with the active site residues of ATAD2 represented by Lidia within Coot. (C) Isothermal titration calorimetry of **7** binding with saturation to ATAD2. (D) ATAD2 represented in solid surface and coloured through conservation of sequence identity between ATAD2 and the first bromodomain of BRD4.

Fig. 2 Overlay of the crystal structures of fragment 17a, 14a, 14b, 17c, 17d, 17f, 17k, 22e and 22c bound to ATAD2. Compounds represented in yellow as ball and stick. Binding pocket of ATAD2 shown in transparent surface, with neighbouring residues of compound shown in stick representation. Conserved waters are represented by red spheres.

Results and discussion

A crystallographic screen of a small targeted library identified pyrrolidinopyridone 7 as a fragment which bound in the

N-acetyllysine histone binding site of the bromodomain of ATAD2 (Fig. 1A and B). Isothermal titration calorimetry (ITC) was used to infer the binding affinity of 7 for the bromodomain of ATAD2, with an apparent K_d of 2.4 mM (Fig. 1C). The pyridone carbonyl forms a hydrogen bond with the carboxamide sidechain of Asn₁₀₆₄, and another through a water-mediated hydrogen bond to Tyr₁₀₂₁, with the *N*⁶-methyl group projecting towards a pocket containing four conserved water molecules. This interaction network mimics the acetylated lysine of the histone, and is consistent with small hydrophobic

Table 1 ATAD2 inhibition data for compounds 7, 14a–g and 17a

ID	R
		ATAD2 IC ₅₀ ^a (μM)	ATAD2 LE	ATAD2 K _d ^b (μM)	BRD4 K _d ^b (μM)
7	H	>1000	N/A	>2000 2400 ^c	>2000
17a	Me	>1000	N/A	>2000	1500
14a	Et	>1000	N/A	1300	12.7
14b	Bn	810 ± 57	0.21	>2000	1050
14c	–CH ₂ CH ₂ Ph	868 ± 33	0.19	1400	800
14d		>1000	N/A	>2000	1700
14e		>1000	N/A	>2000	>2000
14g	–CH ₂ CH ₂ OH	>1000	N/A	>2000	>2000

^a HTRF format assay. ^b SPR format assay. ^c Isothermal titration calorimetry. Ligand efficiency (LE) = 1.4(–log IC₅₀)/*N*, where *N* is number of non-hydrogen atoms.

Table 2 ATAD2 inhibition, SPR and BRD4 binding data for compounds 15c and 17b–d

ID	R ¹	R ²
			ATAD2 IC ₅₀ ^a (μM)	ATAD2 LE	ATAD2 K _d ^b (μM)	BRD4 K _d ^b (μM)
17b	H	Pr	>1000	N/A	>2000	1000
15c	H	Bn	>1000	N/A	2000	1400
17c	Me	Bn	681 ± 120	0.21	700	101
17d	Me	–CH ₂ CH ₂ Ph	741 ± 74	0.20	1000	161

^a HTRF format assay. ^b SPR format assay. Ligand efficiency (LE) = 1.4(–log IC₅₀)/*N*, where *N* is number of non-hydrogen atoms.

groups that occupy the equivalent pocket in other bromodomain family ligands such as the BRD4 inhibitors JQ1²⁰ and I-BET762.²¹ Selectivity over other bromodomain family members is important in the development of a tool compound to investigate the role of the ATAD2 bromodomain in biological systems.²² Minimizing the BET activity of an ATAD2 chemical probe is particularly necessary due to the known effects of BET inhibitors. Thus BRD4 was selected as representative BET family member to assess compound selectivity. The binding orientation of **7** in ATAD2 was designated as binding mode 1 for this template. The residues that line the acetylated lysine binding pocket of BRD4 and ATAD2 are highly conserved (Fig. 1D), with greater divergence in the more solvent exposed

residues including the shelf region of the protein. Achieving selectivity for ATAD2 over BRD4 would thus require identification of fragments that extend away from the conserved core and towards the less conserved areas.

Methylation of the *N*¹ position (**17a**) resulted in a change in binding mode (Fig. 2A), whereby the fragment core rotates and the pyrrolidinone carbonyl now forms a hydrogen bond with the carboxamide sidechain of Asn₁₀₆₄, and a second through a water-mediated hydrogen bond to Tyr₁₀₂₁. In this binding mode the *N*¹-methyl group projects towards the conserved water molecules. Rotation of the pyrrolidinone core allows the pyridone carbonyl to interact through a water molecule with the backbone NH of Asp₁₀₁₄ on the ZA loop. One of the *C*³-geminal methyl groups occupies a small hydrophobic pocket formed between the sidechains of ZA-loop residues Tyr₁₀₂₁, Val₁₀₁₈ and the Tyr₁₀₆₃ residue that reside next to the conserved asparagine. Additional hydrophobic interactions are formed with the base of the binding pocket, where Val₁₀₀₈ and Ile₁₀₇₄ interact with the second *C*³-geminal methyl group and pyrrolidinone core, respectively. This binding orientation was designated as binding mode 2. Intriguingly, when the *N*¹ substituent was further elaborated to an ethyl group (**14a**; Fig. 2B) the compound reverted to binding mode 1, suggesting the conserved water-rich pocket was unable to accommodate the larger ethyl group.

Fragments **7**, **17a**, and **14a** bound very weakly and were unable to displace the acetylated histone ligand sufficiently in a homogeneous time-resolved fluorescence (HTRF) assay to enable a *K*_d to be determined, although some inhibition was observed at the highest concentration assayed (1000 μM; Table 1). Surface plasmon resonance (SPR) was used to assess the direct binding of the fragments and provide *K*_d values for binding to both ATAD2 and BRD4. SPR can yield artefactual data where the concentration of a small-molecular analyte exceeds ~250 μM, and accordingly, this was the highest concentration used in the assays. Where the *K*_d exceeded this

Table 3 ATAD2 inhibition, SPR and BRD4 binding data for compounds **17e–q**

ID	R	ATAD2 IC ₅₀ ^a (μM)	ATAD2 LE	ATAD2 <i>K</i> _d ^b (μM)	BRD4 <i>K</i> _d ^b (μM)
17e	4-CO ₂ Me	651 ± 1	0.18	900	141
17f	4-CO ₂ H	533 ± 40	0.19	600	1500
17g	4-CN	562 ± 67	0.20	900	142
17h	4-CONH ₂	680 ± 66	0.18	700	300
17i	4-SO ₂ Me	359 ± 37	0.19	600	200
17j	4-Cl	190 ± 63	0.24	200	40
17k	4-Br	236 ± 36	0.23	138	48
17l	4-Me	274 ± 75	0.23	400	58
17m	4-CF ₃	179 ± 43	0.21	400	124
17n	3,4-DiCl	299 ± 28	0.21	159	65
17o	2-CN	>1000	N/A	>2000	300
17p	3-CN	668 ± 28	0.19	800	184
17q	2-CO ₂ H	>1000	N/A	>2000	300

^a HTRF format assay. ^b SPR format assay. Ligand efficiency (LE) = 1.4 (−log IC₅₀)/*N*, where *N* is number of non-hydrogen atoms.

Table 4 ATAD2 inhibition, SPR and BRD4 binding data for compounds **22a–f** and **18a–b**

ID	R ¹	R ²	X	ATAD2 IC ₅₀ ^a (μM)	ATAD2 LE	ATAD2 <i>K</i> _d ^b (μM)	BRD4 <i>K</i> _d ^b (μM)
22a	Me	Bn	Cl	>1000	N/A	500	>2000
22b	Me		Cl	>1000	N/A	300	1700
22c	Me		Cl	352	0.17	110	1500
22d	Me	CH ₂ C(CH ₃) ₃	Cl	489 ± 18	0.18	125	>2000
22e	Me		Cl	214	0.19	500	>2000
22f	Me		Cl	304 ± 83	0.20	113	800
18a	Et	Et	Cl	163 ± 23	0.22	107	1000
18b	Et	Et	CF ₃	163 ± 37	0.20	300	>2000

^a HTRF format assay. ^b SPR format assay. Ligand efficiency (LE) = 1.4 (−log IC₅₀)/*N*, where *N* is number of non-hydrogen atoms.

limit, projected K_d s were determined by extrapolation, using the observed response units for compound binding (RU) relative to the molecular weight of a known control compound.²³ Compounds **7** and **17a** bound too weakly to ATAD2 to allow K_d values to be calculated. However, **17a** did show detectable binding to BRD4. Compound **14a** showed a remarkable increase in affinity towards BRD4, reporting a K_d of 12.7 μ M and a binding constant 100-fold weaker towards ATAD2 (Table 1).

The two binding modes offered different vectors to explore structure activity relationships (SARs) of substituents directed towards the RVF shelf and the ZA loop. Thus a set of N^1 -alkylated pyrrolidinopyridones was prepared to attempt to access this region while maintaining binding mode 1 (Table 1). Lipophilic benzyl (**14b**) and phenethyl (**14c**) substituents exhibited sub-millimolar HTRF IC_{50} values, and showed the first detectable signs of direct binding to both ATAD2 and BRD4 when analysed by SPR. Co-crystallisation confirmed that

14b retained binding mode 1 (Fig. 2C). Hydrophilic substituents (**14d–g**) gave no measurable ATAD2 inhibition or binding in HTRF or SPR format experiments.

To attempt to exploit binding mode 2, a set of N^6 -alkylated pyrrolidinopyridones were also prepared (Table 2) with N^6 -benzyl (**17c**) and N^6 -phenethyl (**17d**) analogues giving sub-millimolar ATAD2 IC_{50} values. As expected, **17c** and **17d** retained binding mode 2 (Fig. 2D and E), with the benzyl group sitting above the RVF shelf, forming a hydrophobic interaction with the sidechain of Lys₁₀₁₁. Pairwise comparison with N^1 -des-methyl analogue **15c** confirmed the importance of a methyl group in the conserved water pocket. **17c** and **17d** bound more tightly to BRD4 than to ATAD2 in the SPR experiments.

With the aim of improving binding affinity towards ATAD2 the sidechain of Arg₁₀₀₇ was targeted through substitution of the 4-position of the N^6 -benzyl group. Compound **17f** showed similar ATAD2 affinity to **17c**, and the co-crystal structure with

Fig. 3 Binding interactions of **18a**. (A) Crystal structure of **18a** (yellow ball and stick) within the histone binding site of ATAD2 shown in white ribbon, active site residues shown in cylinder and conserved water molecules shown in red sphere. Key potential hydrogen bonding interactions shown in black dash. (B) Direct binding data using SPR of **18a** with ATAD2 (blue) and BRD4 (green). (C) Superimposition of **18a** bound to ATAD2 with BRD4 showing potential steric clashes of **18a** within the binding site of BRD4 (red). (D) HTRF data of improved potency within the series **17a** pink, **17c** blue, **18a** green.

ATAD2 (Fig. 2F) confirmed that the carboxylate did not form the projected charge–charge interaction with Arg₁₀₀₇. Other analogues bearing functionality with the potential to form hydrogen bonds with Arg₁₀₀₇ gave no further improvement in inhibition (17g–i). Lipophilic substituents at the 4-position of the benzyl group (17j–m, Fig. 2G) provided the most potent benzylic analogues, but continued to be selective for BRD4. Addition of a second chloro substituent at the 3-position (17n) resulted in a modest drop in potency. *N*⁶-Benzyl analogues with substituents at the 2- and 3-positions of the benzylic ring (17o–q) were prepared to attempt to introduce further interactions with the ZA loop, or to favourably influence the conformation of the ligand, but no further improvement in ATAD2 affinity was observed.

Attention turned to exploring substitution at the *C*³-geminal dimethyl group. The *pro-S* methyl group occupies a small lipophilic pocket in the ligand binding site of ATAD2, whereas the *pro-R* methyl provides opportunities for fragment growth. It was envisioned that larger substituents at the *pro-R* position may occupy the cleft between the ZA and BC loops where the substrate acetylated lysine sidechain enters the active site, and may also provide improved selectivity over the more sterically demanding BRD4. Synthetic chemistry to access chiral *C*³ analogues that retained one methyl but differed in the second *C*³ substituent proved challenging, with mono-alkylation strategies found to be low yielding. Knoevenagel condensation was successful when the aldehyde coupling partner did not contain an enolisable proton, allowing the synthesis of 22a–f (Table 4) as racemic mixtures. Symmetrical *C*³-diethyl analogues 18a and 18b were also prepared.

The crystal structure of 18a bound to ATAD2 (Fig. 3A) showed that the diethyl analogues delve further into the hydrophobic pockets formed within the ZA-loop residues Tyr₁₀₂₁, Val₁₀₁₈ and with Ile₁₀₇₄ in the base of the binding site. Gratifyingly, these analogues resulted in a significant improvement in selectivity over BRD4 while retaining ATAD2 binding and inhibition (Table 4) (Fig. 3B).

Superimposition of the crystal structure of 18a with the first bromodomain of BRD4 (PDB entry 2OSS) indicates that the selectivity for ATAD2 over BRD4 may be due to a steric clash of one of the ethyl groups with Leu₉₄ and the other with Ile₁₄₆ in the BRD4 structure (Fig. 3C).

Conclusions

Pyrrolidinopyridone 7 was identified through crystallographic fragment screening as a novel ligand for the ATAD2 bromodomain. Assessment in HTRF, ITC and SPR assays confirmed that this was a low affinity fragment. Structure-guided fragment growing at the *N*¹, *N*⁶ and *C*³ substituents led to the identification of two binding modes for this template in ATAD2. For binding mode 1, methylation of *N*¹, and incorporation of substituted benzyl groups at *N*⁶ led to compounds

with ATAD2 binding affinities below 200 μM (Fig. 3D), but these compounds bound more tightly to BRD4 than to ATAD2. Increasing steric demand at the *C*³ position led to compounds 18a and 18b, retaining ATAD2 binding affinity and activity in the HTRF biochemical assay. These *C*³-substituents conferred selectivity over BRD4 through the introduction of unfavorable interactions with lipophilic amino acid sidechains in the more sterically demanding BRD4 *N*-acetyllysine binding site.

Overall, we have demonstrated that structure-based optimisation of ATAD2 fragments was able to bring millimolar hits into a micromolar potency range. Although inhibition of ATAD2 in the pyrrolidinopyridone series reached a plateau at 100–200 μM, we have succeeded in identifying interactions that can enhance potency while introducing selectivity *versus* BRD4. Application of these lessons might contribute to the development of improved chemical probes of ATAD2's role and structure–function relationship, if applied to fragments with superior initial ligand efficiency.

Author contributions

Duncan C. Miller – Experimental design and interpretation, data analysis, synthesis and characterization of compounds and manuscript preparation.

Mathew Martin – Protein expression, crystallisation and structure determination, assay development and manuscript preparation. †Santosh Adhikari – Synthesis and characterization of compounds.

Alfie Brennan – Synthesis and characterization of compounds.

Jane A. Endicott – Project conception, experimental design and interpretation.

Bernard T. Golding – Experimental design and interpretation, data analysis.

Ian R. Hardcastle – Experimental design and interpretation, data analysis.

Amy Heptinstall – Synthesis and characterization of compounds.

Stephen Hobson – Synthesis and characterization of compounds.

Claire Jennings – Protein expression, crystallisation and structure determination.

Lauren Molyneux – Synthesis and characterization of compounds.

Yvonne Ng – Assay development.

Stephen R. Wedge – Project conception, experimental design and interpretation.

Martin E. M. Noble – Project conception, experimental design and interpretation, data analysis and manuscript preparation.

Céline Cano – Project conception, experimental design and interpretation, data analysis and manuscript preparation (submitting author).

Conflicts of interest

There are no conflicts of interest to declare.

Acknowledgements

The authors thank Cancer Research UK (Grant Reference C2115/A21421) and Astex Pharmaceuticals for financial support. We thank Phil Day and Tom Heightman, Astex Pharmaceuticals for helpful discussions and advice on the crystallography of ATAD2. The use of the EPSRC Mass Spectrometry Service at the University of Wales (Swansea) is also gratefully acknowledged. We also thank beamline staff at The Diamond Light Source who provided excellent facilities for data collection.

References

- 1 A. J. Bannister and T. Kouzarides, *Cell Res.*, 2011, **21**, 381.
- 2 P. Filippakopoulos and S. Knapp, *Nat. Rev. Drug Discovery*, 2014, **13**, 337.
- 3 C. Caron, C. Lestrat, S. Marsal, E. Escoffier, S. Curtet, V. Virolle, P. Barbry, A. Debernardi, C. Brambilla, E. Brambilla, S. Rousseaux and S. Khochbin, *Oncogene*, 2010, **29**, 5171.
- 4 J. X. Zou, L. Guo, A. S. Revenko, C. G. Tepper, A. T. Gemo, H. J. Kung and H. W. Chen, *Cancer Res.*, 2009, **69**, 3339.
- 5 M. Ciró, E. Prosperini, M. Quarto, U. Grazini, J. Walfridsson, F. McBlane, P. Nucifero, G. Pacchiana, M. Capra, J. Christensen and K. Helin, *Cancer Res.*, 2009, **69**, 8491.
- 6 E. V. Kalashnikova, A. S. Revenko, A. T. Gemo, N. P. Andrews, C. G. Tepper, J. X. Zou, R. D. Cardiff, A. D. Borowsky and H. W. Chen, *Cancer Res.*, 2010, **70**, 9402.
- 7 Y. Zhang, Y. Sun, Y. Li, Z. Fang, R. Wang, Y. Pan, H. Hu, X. Luo, T. Ye, H. Li, L. Wang, H. Chen and H. Ji, *Ann. Surg. Oncol.*, 2013, **20**, 577.
- 8 W.-N. Wan, Y.-X. Zhang, X.-M. Wang, Y.-J. Liu, Y.-Q. Zhang, Y.-H. Que and W.-J. Zhao, *Asian Pac. J. Cancer Prev.*, 2014, **15**, 2777.
- 9 H. W. Hwang, S. Y. Ha, H. Bang and C.-K. Park, *Cancer Res. Treat.*, 2015, **47**, 853.
- 10 P. Shang, F. Meng, Y. Liu and X. Chen, *Tumor Biol.*, 2015, **36**, 4479.
- 11 M. J. Zhang, C. Z. Zhang, W. J. Du, X. Z. Yang and Z. P. Chen, *Clin. Transl. Oncol.*, 2016, **18**, 776.
- 12 M. B. Raeder, E. Birkeland, J. Trovik, C. Krakstad, S. Shehata, S. Schumacher, T. I. Zack, A. Krohn, H. M. J. Werner, S. E. Moody, E. Wik, I. M. Stefansson, F. Holst, A. M. Oyan, P. Tamayo, J. P. Mesirov, K. H. Kalland, L. A. Akslen, R. Simon, R. Beroukheim and H. B. Salvesen, *PLoS One*, 2013, **8**, e54873.
- 13 A. Chaikuad, A. M. Petros, O. Fedorov, J. Xu and S. Knapp, *MedChemComm*, 2014, **5**, 1843.
- 14 L. R. Vidler, N. Brown, S. Knapp and S. Hoelder, *J. Med. Chem.*, 2012, **55**, 7346.
- 15 E. H. Demont, C.-w. Chung, R. C. Furze, P. Grandi, A.-M. Michon, C. Wellaway, N. Barrett, A. M. Bridges, P. D. Craggs, H. Diallo, D. P. Dixon, C. Douault, A. J. Emmons, E. J. Jones, B. V. Karamshi, K. Locke, D. J. Mitchell, B. H. Mouzon, R. K. Prinjha, A. D. Roberts, R. J. Sheppard, R. J. Watson and P. Bamborough, *J. Med. Chem.*, 2015, **58**, 5649.
- 16 P. Bamborough, C.-w. Chung, R. C. Furze, P. Grandi, A.-M. Michon, R. J. Sheppard, H. Barnett, H. Diallo, D. P. Dixon, C. Douault, E. J. Jones, B. Karamshi, D. J. Mitchell, R. K. Prinjha, C. Rau, R. J. Watson, T. Werner and E. H. Demont, *J. Med. Chem.*, 2015, **58**, 6151.
- 17 P. Bamborough, C.-w. Chung, E. H. Demont, R. C. Furze, A. J. Bannister, K. H. Che, H. Diallo, C. Douault, P. Grandi, T. Kouzarides, A.-M. Michon, D. J. Mitchell, R. K. Prinjha, C. Rau, S. Robson, R. J. Sheppard, R. Upton and R. J. Watson, *Angew. Chem., Int. Ed.*, 2016, **55**, 11382.
- 18 M. J. Harner, B. A. Chauder, J. Phan and S. W. Fesik, *J. Med. Chem.*, 2014, **57**, 9687.
- 19 A. E. Fernández-Montalván, M. Berger, B. Kuropka, S. J. Koo, V. Badock, J. Weiske, V. Puetter, S. J. Holton, D. Stöckigt, A. ter Laak, P. A. Centrella, M. A. Clark, C. E. Dumelin, E. A. Sigel, H. H. Soutter, D. M. Troast, Y. Zhang, J. W. Cuzzo, A. D. Keefe, D. Roche, V. Rodeschini, A. Chaikuad, L. Díaz-Sáez, J. M. Bennett, O. Fedorov, K. V. M. Huber, J. Hübner, H. Weinmann, I. V. Hartung and M. Gorjánácz, *ACS Chem. Biol.*, 2017, **12**, 2730.
- 20 P. Filippakopoulos, J. Qi, S. Picaud, Y. Shen, W. B. Smith, O. Fedorov, E. M. Morse, T. Keates, T. T. Hickman, I. Felletar, M. Philpott, S. Munro, M. R. McKeown, Y. Wang, A. L. Christie, N. West, M. J. Cameron, B. Schwartz, T. D. Heightman, N. La Thangue, C. A. French, O. Wiest, A. L. Kung, S. Knapp and J. E. Bradner, *Nature*, 2010, **468**, 1067.
- 21 C.-w. Chung, H. Coste, J. H. White, O. Mirguet, J. Wilde, R. L. Gosmini, C. Delves, S. M. Magny, R. Woodward, S. A. Hughes, E. V. Boursier, H. Flynn, A. M. Bouillot, P. Bamborough, J.-M. G. Brusq, F. J. Gellibert, E. J. Jones, A. M. Riou, P. Homes, S. L. Martin, I. J. Uings, J. Toum, C. A. Clément, A.-B. Boullay, R. L. Grimley, F. M. Blandel, R. K. Prinjha, K. Lee, J. Kirilovsky and E. Nicodeme, *J. Med. Chem.*, 2011, **54**, 3827.
- 22 P. Workman and I. Collins, *Chem. Biol.*, 2010, **17**, 561.
- 23 A. M. Giannetti, in *Methods Enzymol.*, ed. L. C. Kuo, Academic Press, Editon edn., 2011, vol. 493, pp. 169.